Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma 18Lymphoma, Non-Hodgkin 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Hodgkin Disease 11Lymphoma, Large B-Cell, Diffuse 9Central Nervous System Neoplasms 9Leukemia, Myeloid, Acute 8Neuroblastoma 7Multiple Myeloma 7Leukemia 7Brain Neoplasms 7Small Cell Lung Carcinoma 6Sarcoma 6Lymphoma, Large-Cell, Immunoblastic 6Lymphoma, Mantle-Cell 5Lymphoma, Follicular 5Leukemia, Lymphocytic, Chronic, B-Cell 5Lymphoma, B-Cell, Marginal Zone 4Carcinoma, Non-Small-Cell Lung 4Burkitt Lymphoma 4Testicular Neoplasms 3Teratoma 3Rhabdoid Tumor 3Medulloblastoma 3Lung Neoplasms 3Astrocytoma 3Waldenstrom Macroglobulinemia 2Testicular Germ Cell Tumor 2Rhabdomyosarcoma 2Recurrence 2

Interventions

Cytarabine 9fludarabine 5Imatinib Mesylate 5thymoglobulin 3fludarabine phosphate 3Tacrolimus 3Sirolimus 3Methotrexate 3Cyclophosphamide 3Busulfan 3Azacitidine 3zosuquidar trihydrochloride 2venetoclax 2ponatinib 2nilotinib 2enasidenib 2bosutinib 2RO6839921 2Mycophenolic Acid 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Etoposide 2Behavior Therapy 2Antilymphocyte Serum 24-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide 2spartalizumab 1sabatolimab 1quizartinib 1plerixafor 1pegfilgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Leukemia, Myeloid × etoposide phosphate × Clear all
NCT01411267 2022-04-04

AC220 for Children With Relapsed/Refractory ALL or AML

Therapeutic Advances in Childhood Leukemia Consortium

Phase 1 Completed
24 enrolled 14 charts
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Myeloid, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡